Literature DB >> 16339796

Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin.

Anna-Leena Sirén1, Konstantin Radyushkin, Susann Boretius, Daniel Kämmer, Claas-Christian Riechers, Oliver Natt, Derya Sargin, Takashi Watanabe, Swetlana Sperling, Thomas Michaelis, Jack Price, Barbara Meyer, Jens Frahm, Hannelore Ehrenreich.   

Abstract

In humans, neurotrauma is suspected to cause brain atrophy and accelerate slowly progressive neurodegenerative disorders, such as Alzheimer's disease or schizophrenia. However, a direct link between brain injury and subsequent delayed global neurodegeneration has remained elusive. Here we show that juvenile (4-week-old) mice that are given a discrete unilateral lesion of the parietal cortex, develop to adulthood without obvious clinical symptoms. However, when monitored 3 and 9 months after lesioning, using high-resolution three-dimensional MRI and behavioural testing, the same mice display global neurodegenerative changes. Surprisingly, erythropoietin, a haematopoietic growth factor with potent neuroprotective activity, prevents behavioural abnormalities, cognitive dysfunction and brain atrophy when given for 2 weeks after acute brain injury. This demonstrates that a localized brain lesion is a primary cause of delayed global neurodegeneration that can be efficiently counteracted by neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339796     DOI: 10.1093/brain/awh703

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  37 in total

1.  Cerebral tissue repair and atrophy after embolic stroke in rat: a magnetic resonance imaging study of erythropoietin therapy.

Authors:  Guangliang Ding; Quan Jiang; Lian Li; Li Zhang; Ying Wang; Zheng Gang Zhang; Mei Lu; Swayamprava Panda; Qingjiang Li; James R Ewing; Michael Chopp
Journal:  J Neurosci Res       Date:  2010-11-01       Impact factor: 4.164

2.  Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis.

Authors:  Claudia Bartels; Kira Späte; Henning Krampe; Hannelore Ehrenreich
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

3.  Regional brain injury on conventional and diffusion weighted MRI is associated with outcome after pediatric cardiac arrest.

Authors:  Ericka L Fink; A Panigrahy; R S B Clark; C R Fitz; D Landsittel; P M Kochanek; G Zuccoli
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

Review 4.  Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

5.  Persistent region-dependent neuroinflammation, NMDA receptor loss and atrophy in an animal model of penetrating brain injury.

Authors:  Rachel Grossman; Charles M Paden; Pamela A Fry; Ryon Sun Rhodes; Anat Biegon
Journal:  Future Neurol       Date:  2012-05-01

6.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

7.  Neuroprotective effects of ischemic preconditioning on global brain ischemia through up-regulation of acid-sensing ion channel 2a.

Authors:  Yifeng Miao; Weiqiao Zhang; Yuchang Lin; Xiaojie Lu; Yongming Qiu
Journal:  Int J Mol Sci       Date:  2010-01-12       Impact factor: 5.923

Review 8.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

9.  Safety of intravitreally administered recombinant erythropoietin (an AOS thesis).

Authors:  James C Tsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.